Skip to Main Content

Paper Details

EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma.
Sci Rep
13
2021
Akt, EZH1, EZH1/2, EZH2, EZH2lowH3K27me3high, H3K27, H3K27) methyltransferases, H3K27me3, HCC, Lysine, UNC1999, cancers, hepatocellular carcinoma, histone H3 Lysine 27 (, liver cancer, liver cancer cells, serine, sorafenib, target genes, tumor
Author NameAffiliation
Jian JinMount Sinai Center for Therapeutics Discovery, Icahn School of Medicine at Mount Sinai
Jian JinDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai
Jian JinTisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Atsushi IwamaCenter for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo
Atsushi IwamaGraduate School of Medicine, Chiba University
  • 1 - 5

Datasets

Release 1.2